Abstract:Introduction: Cardiovascular diseases have been the leading causes of death all over the world for decades. Vascular smooth muscle cells (VSMCs) form a major section of a blood vessel, conferring structural and physiological support to withstand any change under physiological or pathological conditions. VSMC phenotypic modulation from a contractile phenotype to a synthetic state is pivotal for the development of several vascular diseases such as neointima formation after angioplasty and atherosclerosis. Decreased expression of VSMC differentiation markers including SM ɑ-actin (Acta2), SM-myosin heavy chain (Myh11) and SM22 alpha (Tagln) indicates VSMC phenotypic switching, which is accompanied by increasing VSMC proliferation, migration and synthesis of metalloproteinase[1]. However, the molecular mechanisms that underlie VSMC phenotypic switching remain largely unknown. SMYD2, a SET and MYND domain-containing protein, belongs to the SMYD family of protein lysine methyltransferases. Structurally, SET domain regulates lysine methylation of target proteins (as involved in transcription, cell differentiation and cell proliferation), while zinc finger motif MYND domain may interact with proline rich regions and facilitate protein-protein interaction. SMYD2 was originally reported to methylate histone 3 at lysine 4 (H3K4) and lysine 36 (H3K36) and H4 at lysine 20 (H4K20), and plays an essential role in HIV-1 latency and cardiac development [2-3]. Some studies found that SMYD2 can also methylate non-histone proteins such as p53, Hsp90, and Rb and regulate their functions [4-6]. Interestingly, SMYD2 has recently been implicated in human patients with abdominal aortic aneurysm in GWAS screening [7]. The aim of this study is to investigate the role of SMYD2 in the control of VSMC phenotypic switching and neointima formation. Methods: We used Western blotting and PCR to assess SMYD2 expression and VSMC marker gene expression in VSMC phenotypic change in vitro and murine carotid ligation injury model in vivo. In the ligation injury model, right common carotid artery (CCA) was ligated and harvested after 7, 14, and 28 days. SMYD2smc-/- (SMYD2 conditional knockout in VSMCs) mice and SMYD2flox/flox (SMYD2 flox control) mice were subjected to ligation model and CCA was obtained for histological evaluation after7 days, 14 days and 28days. Primary VSMCs were isolated from SMYD2smc-/- mice and SMYD2flox/flox mice and then VSMC marker gene expression was examined by Western blotting and PCR. Furthermore, we also checked expression of SMYD2 in murine atherosclerosis which is closely related to VSMC phenotypic change. Results: The expression of SMYD2 significantly decreased in response to platelet-derived growth factor BB (PDGF-BB) in the serum-starved VSMCs. In the in vivo model, we found that SMYD2 expression was also reduced in the injured versus sham-operated carotid arteries. In comparison with normal healthy arteries, atherosclerotic arteries have a substantially decreased SMYD2 expression in mouse vascular tissues. Moreover, SMYD2 ablation in VSMCs significantly exacerbated ligation injury-induced neointima formation in mice and drastically inhibited VSMC marker gene expression. Conclusion: Our findings demonstrated that SMYD2 down-regulation in VSMCs promotes VSMC phenotypic changing and neointima formation after injury, suggesting that SMYD2 may function as a novel inhibitor of vascular remodeling associated with physical injury and atherosclerotic disease. Disclosure: Nothing to disclose

Synthetic VSMCs induce BBB disruption mediated by MYPT1 in ischemic stroke

Abstract 137: Vascular Smooth Muscle Cell MYPT1 Deficiency Induces Phenotype Switching and Disrupts Blood-Brain Barrier after Stroke

Hippo/MST1 Signaling Mediates Microglial Activation Following Acute Cerebral Ischemia–reperfusion Injury

Abstract 3142: Pik3c3 Safeguards Smooth Muscle Identity by Promoting Lysosome-mediated Yap1 Degradation

A Mechanistic Systems Biology Model of Brain Microvascular Endothelial Cell Signaling Reveals Dynamic Pathway-Based Therapeutic Targets for Brain Ischemia

PDGFR-β modulates vascular smooth muscle cell phenotype via IRF-9/SIRT-1/NF-κB pathway in subarachnoid hemorrhage rats.

Activation of BMP4-pSmad1/5 Pathway Impairs the Function of VSMCs in Intracranial Aneurysms.

Endothelial Conditional Knockdown of NMMHC IIA (Nonmuscle Myosin Heavy Chain IIA) Attenuates Blood-Brain Barrier Damage During Ischemia-Reperfusion Injury.

MYPT1SMKO Mice Function As a Novel Spontaneous Age- and Hypertension-Dependent Animal Model of CSVD

Interstitial Fluid Shear Stress Induces the Synthetic Phenotype Switching of VSMCs to Release Pro-calcified Extracellular Vesicles Via EGFR-MAPK-KLF5 Pathway

Overexpression of mitogen-activated protein kinase phosphatase-1 in endothelial cells reduces blood-brain barrier injury in a mouse model of ischemic stroke

Mitochondria‐associated endoplasmic reticulum membranes tethering protein VAPB‐PTPIP51 protects against ischemic stroke through inhibiting the activation of autophagy

Histone Methyltransferase Smyd2 Contributes to Blood‐brain Barrier Breakdown in Stroke

M1-type microglia-derived exosomes contribute to blood–brain barrier damage

Organoid Modeling and Single-Cell Profiling Uncover the Migration Mechanism of Smooth Muscle Cells in Moyamoya Disease

Set and MYND Domain-containing Protein 2 (SMYD2) is a Critical Regulator for Vascular Smooth Muscle Cell Phenotypic Switching and Neointima Formation

Specific mode electroacupuncture stimulation opens the blood–brain barrier of the infarcted border zone in rats during MCAO/R recovery via modulation of tight junction protein expression by VEGFA and NF-κB

Endothelial Myosin IIA Is Required for the Maintenance of Blood–Brain Barrier Integrity

Abstract P749: Functional and Molecular Characterization of Endothelial and Vascular Smooth Muscle Cells Derived From Moyamoya Disease-Induced Pluripotent Stem Cells

Smooth muscle SIRT1 reprograms endothelial cells to suppress angiogenesis after ischemia

Mesenchymal stem cell-derived extracellular vesicles attenuate tPA-induced blood-brain barrier disruption in murine ischemic stroke models